- Bayer to present extensive new data from its oncology portfolio at ...🔍
- Bayer presents latest data from oncology portfolio at 2024 ASCO ...🔍
- Bayer to Present New Prostate Cancer Data and Continued ...🔍
- Bayer presents new data across oncology portfolio at the 2023 ...🔍
- Articles tagged with 'Cancer'🔍
- Bayer Presents Latest Data from Oncology Portfolio at 2024 ASCO ...🔍
- Articles tagged with 'doccheck|en'🔍
- Articles tagged with 'export|latestnews'🔍
Bayer to present extensive new data from its oncology portfolio at ...
This is Bayer Health Agriculture Products Innovation Sustainability Media Investors Career This news release (German version) is protected by “DocCheck”
Bayer will showcase latest prostate cancer data for darolutamide and targeted alpha therapy radium-223 dichloride / Bayer will also present ...
Bayer to Present New Prostate Cancer Data and Continued ...
Bayer to Present New Prostate Cancer Data and Continued Oncology Portfolio Research at ESMO 2024 ... NUBEQA is indicated in the U.S. for the ...
ESMO 2024: Bayer to Present New Prostate Cancer Data and ...
Bayer will also highlight an updated analysis from the SCOUT (pediatric participants) and NAVIGATE (adult and pediatric participants) studies evaluating the ...
Real-world safety and effectiveness data from the REASSURE study involving patients with metastatic castration-resistant prostate cancer (mCRPC) treated with ...
Bayer to present extensive new data from its oncology portfolio at ESMO 2024. Bayer will reveal late-breaking data from the Phase III ARANOTE trial in ...
Bayer | Pharmaceuticals on X: "#TeamBayer is excited to present ...
TeamBayer is excited to present pivotal new data from our comprehensive oncology portfolio, and we look forward to engaging in meaningful ...
Bayer Presents Latest Data from Oncology Portfolio at 2024 ASCO ...
The breadth of new data in different tumor types underscores Bayer's ambition to deliver innovative and effective oncological therapies in areas with the ...
Bayer to present extensive new data from its oncology portfolio at ESMO 2024. Bayer will reveal late-breaking data from the Phase III ARANOTE trial in ...
Bayer to present extensive new data from its oncology portfolio at ESMO 2024. Bayer will reveal late-breaking data from the Phase III ARANOTE trial in ...
Bayer and Broad Institute extend cancer therapy research ...
Bayer and the Broad Institute of MIT and Harvard have renewed their research alliance, adding five years to a 10-year collaboration that has already yielded ...
Bayer continues to focus on advancing prostate cancer care from early to metastatic stage with darolutamide data in non-metastatic ...
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
... label update that occurs in oncology and hematology. Please refer to Drugs@FDA for the latest approvals and prescribing information for specific products.
Bayer HealthCare - Main Sponsors | OncologyPRO
The oncology franchise at Bayer now expands to six marketed products and several other assets in various stages of clinical development. Together, these ...
Bayer, Broad expand partnership to advance cancer drug discovery ...
Bayer and the Broad Institute of MIT and Harvard announced today that they have extended their multi-disciplinary research partnership by an additional five ...
Merck to Present New Data at 2024 ASCO Annual Meeting ...
As Merck continues to build its broad oncology portfolio, the company will also present data at ASCO from its diverse pipeline of ...
Bayer announces new data on oncology portfolio
Data from a recently unblinded phase II trial evaluating the safety and efficacy of Nexavar as a potential treatment for breast cancer will be ...
Bayer Presents Latest Data and New Research to Advance Cancer ...
WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer will present new data across its oncology portfolio at the 2021 American Society of Clinical ...
Bayer to present extensive new data from its oncology portfolio at ESMO 2024. Bayer will reveal late-breaking data from the Phase III ARANOTE trial in ...
News Release - Investor Relations | Regeneron Pharmaceuticals Inc.
(NASDAQ: REGN) today announced new and updated data from its oncology and hematology pipeline will be shared across 17 presentations at the ...